Skip to main content
. 2021 Aug;10(3):154–164. doi: 10.5582/irdr.2021.01022

Table 2. Small molecule inhibitors targeting JAK.

JAK inhibitor Molecular target Mechanism of action Phase
Tofacitinib JAK1, JAK3 Interferes with the binding of IL-6 to the IL-6Rα/gp130 complex, STAT proteins Appeared on the market in 2017
Baricitinib JAK1, JAK2 Blocks intracellular signaling, facilitates the turnover of active (phosphorylated) STAT1 and STAT3 Appeared on the market in 2018
Filgotinib JAK1 Blocks intracellular signaling, facilitates the turnover of active (phosphorylated) STAT1 Phase III
Peficitinib JAK1, JAK3 Interferes with the binding of IL-6 to the IL-6Rα/gp130 complex, STAT proteins Phase III
SHR0302 JAK1 Blocks intracellular signal transduction, facilitates the turnover of active (phosphorylated) STAT1 Phase II